Navigation Links
New Institute Paves Way for Rapid Cancer Drug Development
Date:10/12/2010

GREENVILLE, S.C., Oct. 12 /PRNewswire-USNewswire/ -- Greenville Hospital System University Medical Center (GHS) unveiled details of its new Institute for Translational Oncology Research, a visionary cancer initiative that will help pave the way for new breakthroughs in rapid drug development, diagnostic discovery and advanced cancer care. ITOR is part of the GHS Cancer Center, a recognized regional multi-disciplinary center.

ITOR partners will include leading pharmaceutical companies, research universities, private industry and the government. GHS made the announcement today (Oct. 12).

The new institute, known as ITOR, builds on the success of GHS' Clinical Research Unit and its rapidly-developing biorepository tissue-banking service, which helped make GHS one of the country's prominent players in the development of promising new oncology drugs. Numerous first-in-human studies have been conducted through the CRU, which began in 2004 as part of GHS' long-standing relationship with Cancer Centers of the Carolinas.  

The evolving institute is steadily moving into the arena of personalized gene-based cancer therapies, which match the treatment to tumor-specific genetic abnormalities and patient-specific predictors of toxicity. Such translational research helps bring discovery directly from the lab to practical applications in patients. Part of ITOR's strength is its focus on using innovative public and private sector partnerships and initiatives to advance leading-edge cancer care.

"Through ITOR, we will be able to make new therapies accessible to patients far more quickly than traditional models have allowed," said Joe Stephenson, M.D., who serves as the institute's medical director.

To accomplish the goal of speeding-up the delivery of patient-specific therapies, ITOR strives to identify new ways to achieve earlier prediction of drug success, find new applications and patients for existing drugs and integrate advanced molecular and gene-based technologies into diagnostic and treatment protocols.

In practical terms, that means ITOR is focused on developing a more personalized approach to cancer therapy – targeting the right drug to the right patient – by integrating leading-edge technologies such as molecular profiling into an enhanced drug validation process.

Pharmaceutical and industry partners include long-time collaborator U.S. Oncology, Caris Life Sciences and Lab21, as well as Amgen, AstraZeneca, Japanese-based Eisai Pharmaceuticals, Oncolix and Novartis, which recently selected ITOR as one of its newest designated phase 1 clinical trial sites. Early academic partners also include the Cancer Research Center of the University of South Carolina.

For a complete list of partners and more information on ITOR, go to ITOR-ghs.org.


'/>"/>
SOURCE Greenville Hospital System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ECRI Institute Names Kaiser Permanente Winner of 5th Annual Health Devices Achievement Award
2. ACD Wins $3 Million Grant From National Cancer Institute to Develop Its CTCscope™ System for Detection and Molecular Analysis of Circulating Tumor Cells
3. Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)
4. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
5. West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0
6. Roskamp Institute to Begin Human Alzheimers Clinical Trials With a Natural Compound in Tobacco
7. American College of Surgeons Health Policy Research Institute Releases Surgery Workforce Atlas That Shows Surgeon Shortage Across the U.S.
8. Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
9. The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K
10. National Pharmaceutical Council Comments on Patient-Centered Outcomes Research Institute Board of Governors
11. Wolters Kluwer Health and the Joanna Briggs Institute Enter Exclusive Relationship to Deliver Evidence-Based Clinical Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)...  Sequent Medical, Inc. announced today that it has ... safety and effectiveness of the WEB™ Aneurysm Embolization System ... Prof Laurent Spelle , MD, Head of Neuroradiology ... and Principal Investigator of the CLARYS study, ... and Germany.  Although patients with ruptured aneurysms have ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... WILMINGTON, North Carolina , 12 februari ... Laboratories, Inc. (AAI/CML), een toonaangevende leverancier van ... farmaceutische en biotechnologische industrieën, kondigt vandaag een ... en mogelijkheden op haar locatie in ... in vraag heeft geleid tot meerdere recente ...
Breaking Medicine Technology:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Prater Eye Center becomes the first in the area to offer AngioPlex™ Optical ... signs of retinal disease, such as macular degeneration, diabetic retinopathy, and other vascular ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... Many individuals ... of protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved ... it once more, but without the high-carb repercussions. IsoPasta has 30 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, ... gift of a VeinViewer® Vision vein finder for the nursing school ... an IV and draw blood, combining technology with traditional technique. , “VeinViewer is ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... According ... hernia surgeries are beginning to account for a significant portion of hernia repairs throughout ... Towfigh of the Beverly Hills Hernia Center notes that this trend has not only ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted over 250 members of South Florida’s philanthropic community at its 10th ...
Breaking Medicine News(10 mins):